Article Sidebar

PDF
Date Published: 26/08/2022
Abstract Views: 149
Views PDF: 114
DOI: https://doi.org/10.51298/vmj.v517i2.3228
Issue
Vol. 517 No. 2 (2022)
Section
Các bài báo
How to Cite
Hùng Kiên, Đỗ ., & Văn Tài, N. . (2022). RESPONSE RESULTS AND ANALYZING THE RELATED FACTORS OF FIRST-LINE PACLITAXEL/CARBOPLATIN CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED/ METASTATIC SQUAMOUS CELL LUNG CANCER PATIENTS AT NATIONAL CANCER HOSPITAL. Vietnam Medical Journal, 517(2). https://doi.org/10.51298/vmj.v517i2.3228

RESPONSE RESULTS AND ANALYZING THE RELATED FACTORS OF FIRST-LINE PACLITAXEL/CARBOPLATIN CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED/ METASTATIC SQUAMOUS CELL LUNG CANCER PATIENTS AT NATIONAL CANCER HOSPITAL

Đỗ Hùng Kiên1,, Nguyễn Văn Tài1
1 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objective: Assessing the response results and analyzing the related factors of paclitaxel/carboplatin chemotherapy for the treatment of advanced/ metastatic squamous cell lung cancer patients at National Cancer Hospital from 01/2017 to 05/2022. Patients and method: Retrospective and prospective analysis of 65 patients with advanced/ metastatic squamous cell lung carcinoma were diagnosed and treated with paclitaxel/carboplatin regimen at National Cancer Hospital from 01/2017 to 05/2022. Results: During the treatment of first-line paclitaxel/carboplatin chemotherapy of 65 advanced/metastatic squamous cell lung cancer patients, the response rate was 38.5%; the control disease rate was 66.2%, progressive rate was 33.8%. Most of patients had improved the clinical symptoms during the treatement (accounting for 47.7%). Patients with ECOG 0 had higher response rates than one with ECOG 1, there was a significant difference with p=0,002. Conclusion: The overall response rate of first-line paclitaxel/carboplatin chemotherapy for the treatment of advanced/metastatic squamous cell lung cancer was 38.5%, the control rate was 66.2%. Patients with good performance status had higher response rate.

Article Details

Keywords

Squamous cell lung cancer, advanced/ metastatic stage, paclitaxel/carboplatin, National Cancer Hospital

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71, 209–249, doi:10.3322/caac.21660.
2. Cheng, T.-Y.D.; Cramb, S.M.; Baade, P.D.; Youlden, D.R.; Nwogu, C.; Reid, M.E. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J. Thorac. Oncol. 2016, 11, 1653–1671, doi:10.1016/j.jtho.2016.05.021.
3. Lortet-Tieulent, J.; Soerjomataram, I.; Ferlay, J.; Rutherford, M.; Weiderpass, E.; Bray, F. International Trends in Lung Cancer Incidence by Histological Subtype: Adenocarcinoma Stabilizing in Men but Still Increasing in Women. Lung Cancer 2014, 84, 13–22, doi:10.1016/j.lungcan.2014.01.009.
4. Socinski, M.A.; Obasaju, C.; Gandara, D.; Hirsch, F.R.; Bonomi, P.; Bunn, P.A.; Kim, E.S.; Langer, C.J.; Natale, R.B.; Novello, S.; et al. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J. Thorac. Oncol. 2018, 13, 165–183, doi:10.1016/j.jtho.2017.11.111.
5. Soldera, S.V.; Leighl, N.B. Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Front. Oncol. 2017, 7.
6. Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2040–2051, doi:10.1056/ NEJMoa1810865.
7. Herbst, R.S.; Giaccone, G.; de Marinis, F.; Reinmuth, N.; Vergnenegre, A.; Barrios, C.H.; Morise, M.; Felip, E.; Andric, Z.; Geater, S.; et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N. Engl. J. Med. 2020, 383, 1328–1339, doi:10.1056/ NEJMoa1917346.
8. Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833, doi:10.1056/ NEJMoa1606774.
9. Rosell, R.; Gatzemeier, U.; Betticher, D.C.; Keppler, U.; Macha, H.N.; Pirker, R.; Berthet, P.; Breau, J.L.; Lianes, P.; Nicholson, M.; et al. Phase III Randomised Trial Comparing Paclitaxel/Carboplatin with Paclitaxel/Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer: A Cooperative Multinational Trial. Ann. Oncol. 2002, 13, 1539–1549, doi:10.1093/ annonc/mdf332.